Patients in RCT1 received intravenous placebo , 30-mg tabalumab or 80-mg tabalumab every 3weeks , and patients in RCT2 received subcutaneous placebo or 1 - , 3 - , 10 - , 30 - , 60 - or 120-mg tabalumab every 4weeks ( Q4W ) .